Journal for ImmunoTherapy of Cancer (Nov 2023)

384 Single-cell transcriptomics, proteomics and in vitro cytotoxicity of allogeneic cryopreserved natural killer cell therapy GTA002 identify potent effector signatures

Jan Spanholtz,
Monica Raimo,
Daniëlle Steenmans,
Amanda van Vliet,
Anna-Maria Georgoudaki,
Adil Duru,
Denise Vodegel

Affiliations

Jan Spanholtz: Glycostem Therapeutics, Oss, Netherlands
Monica Raimo: Glycostem Therapeutics, Oss, Netherlands
Daniëlle Steenmans: Glycostem Therapeutics, Oss, Netherlands
Amanda van Vliet: Glycostem Therapeutics, Oss, Netherlands
Anna-Maria Georgoudaki: Glycostem Therapeutics, Oss, Netherlands
Adil Duru: Glycostem Therapeutics, Oss, Netherlands
Denise Vodegel: Glycostem Therapeutics, Oss, Netherlands

DOI: https://doi.org/10.1136/jitc-2023-SITC2023.0384
Journal volume & issue: Vol. 11, no. Suppl 1

Abstract

No abstracts available.

Published in Journal for ImmunoTherapy of Cancer

ISSN: 2051-1426 (Online)
Publisher: BMJ Publishing Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://jitc.bmj.com

About the journal